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Abstract
In order to generate genomic signals, the androgen receptor (AR) has to be transported into the nucleus upon androgenic
stimuli. However, there is evidence from in vitro experiments that in castration-resistant prostate cancer (CRPC) cells the AR
is able to translocate into the nucleus in a ligand-independent manner. The recent finding that inhibition of the glycogen-
synthase-kinase 3b (GSK-3b) induces a rapid nuclear export of the AR in androgen-stimulated prostate cancer cells
prompted us to analyze the effects of a GSK-3b inhibition in the castration-resistant LNCaP sublines C4-2 and LNCaP-SSR.
Both cell lines exhibit high levels of nuclear AR in the absence of androgenic stimuli. Exposure of these cells to the
maleimide SB216763, a potent GSK-3b inhibitor, resulted in a rapid nuclear export of the AR even under androgen-deprived
conditions. Moreover, the ability of C4-2 and LNCaP-SSR cells to grow in the absence of androgens was diminished after
pharmacological inhibition of GSK-3b in vitro. The ability of SB216763 to modulate AR signalling and function in CRPC in vivo
was additionally demonstrated in a modified chick chorioallantoic membrane xenograft assay after systemic delivery of
SB216763. Our data suggest that inhibition of GSK-3b helps target the AR for export from the nucleus thereby diminishing
the effects of mislocated AR in CRPC cells. Therefore, inhibition of GSK-3b could be an interesting new strategy for the
treatment of CRPC.
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Introduction
Transcriptional regulation by nuclear receptors plays a pivotal
role in the development and growth of prostate cancer (PC) cells.
This is well exemplified by the role of the androgen receptor (AR),
a ligand-activated transcription factor belonging to the steroid
receptor superfamily. In the absence of androgens, the AR is
predominantly located in the cytoplasm stabilized by a multi-
chaperone complex [1]. Upon binding of androgens, the AR is
thought to undergo a conformational change leading to a
homodimerization with another AR protein after dissociation
from parts of the multichaperone-complex [2]. Subsequently, the
AR is actively transported into the nucleus where it binds to
specific DNA-sequences termed androgen response elements
(ARE) found within promoter or enhancer regions of AR target
genes [3] thereby activating the general transcription apparatus
[4].
The initial androgen dependency of prostate cancer cells is the
reason why most PC respond to androgen ablation therapy.
Unfortunately, the benefit of androgen ablation is only transitory.
After a period of around two years, PC almost invariably progress
to a state of the disease termed castration-resistant prostate cancer
(CRPC) where tumor cells can grow and survive under castrate
levels of circulating androgens. Although the in vitro development
of an androgen-independent phenotype is mostly based on the loss
of the AR in tumor cells, there is evidence from several clinical
studies that the AR is rarely lost in CRPC cells in vivo [5,6].
Furthermore, these studies suggest that resistance to conventional
hormonal therapy is not due to a loss of androgen sensitivity but
rather may be a consequence of a deregulated AR-signalling axis
[7].
In order to generate genomic signals in hormone-dependent PC
cells the AR must be transported into the nucleus upon androgenic
stimuli. There is compelling evidence from in vitro experiments that
in a subset of CRPC cells, the AR acquires the ability to undergo
ligand-independent shuttling from the cytoplasm to the nucleus
[8]. Most interestingly, in these cells the AR displays a high level of
constitutive, androgen-independent activity [9]. As the nuclear
presence of the receptor is a prerequisite for AR signalling,
regulation of nuclear translocation might reveal new strategies for
the treatment of both androgen-dependent PC as well as CRPC.
Various studies have offered insights into the nuclear import of
the AR. A bipartite nuclear localization sequence (NLS) has been
identified in the DNA binding domain (DBD) and hinge region of
the AR [10]. This NLS utilizes the classical importin pathway for
transport through the nuclear pore complex [11,12]. In addition, a
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the AR [13,14]. In contrast to the nuclear import of the AR, the
mechanisms involved in AR nuclear export are poorly understood.
The DNA binding domains (DBD) of diverse steroid receptors
have been suggested to function as nuclear export signals (NES) for
a calreticulin mediated nuclear export [15]. However, for the AR
these data have been discussed controversially [16,17]. Recently,
Saporita et al. reported the identification of a novel NES (amino
acids 743–817) situated in the LBD of the AR [18]. The
identification of a NES in the LBD of the AR is in agreement
with previous findings of our group studying the nuclear export of
the AR in androgen-stimulated PC cells after inhibition of the
glycogen-synthase-kinase 3b (GSK-3b) [19].
The finding that inhibition of GSK-3b induces a rapid nuclear
export of the AR in androgen-stimulated PC cells prompted us to
analyze the effects of GSK-3b inhibition in castration-resistant
LNCaP sublines C4-2 and LNCaP-SSR [20,21], both known to
exhibit high levels of nuclear AR in the absence of androgenic
stimuli. Both in vitro as well as in vivo data presented in this study
suggest that induction of nucleocytoplasmic AR export might be a
useful strategy to diminish AR signalling, especially in advanced
CRPC.
Results
AR and GSK-3b are up-regulated in CRPC cell lines
In order to analyze the effects of GSK-3b inhibitors on AR-
activity in CRPC cells we first determined endogenous AR or
GSK-3b levels in whole cell extracts of PC cells grown in the
absence of DHT. The AR-positive LNCaP sublines C4-2 and
LNCaP-SSR, known to proliferate in the absence of androgens,
served as models for CRPC [20,21]. The androgen-sensitive
LNCaP as well as the AR-negative PC3 cells served as controls. As
seen in Figure 1A, the AR was detectable in all LNCaP lines
grown in the absence of the AR-stabilizing androgen DHT.
Intracellular AR levels were significantly increased in the AR-
positive CRPC cells (C4-2 +177%, LNCaP-SSR +126%) (Table 1).
The increase of AR-protein in castration-resistant LNCaP sublines
was paralleled by an increase in PSA (C4-2 +337% and LNCaP-
SSR +110%, respectively), the latter suggesting that the AR is
particularly active in these cells (Figure 1A, B; Table 1). Western
blot analysis of intracellular GSK-3b protein revealed significantly
higher intracellular GSK-3b levels in C4-2 (+361%) and LNCaP-
SSR (+150%) cells in comparison to the parental LNCaP cells
(Figure 1A, Table 1).
The maleimide SB216763 reduces GSK-3b-activating
phosphorylation at tyrosine 216
Several studies reported that the majority of the GSK-3b
molecules are inactive in LNCaP cells as a result of a
phosphorylation at serine 9 (S9) [26,27]. However, there is
experimental evidence that GSK-3b activity it is not fully inhibited
in LNCaP cells [28,29,30,31,32]. Following DHT treatment,
phosphorylation of GSK-3b at tyrosine 216 (GSK-3b
Y216), a
GSK-3b-activating phosphorylation site, was increased in LNCaP
and C4-2 cells (Fig. 2). In order to inhibit residual GSK-3b activity
in LNCaP and C4-2 cells, cells were treated with the maleimide
SB216763, a GSK-3b inhibitor recently shown to inhibit the
phosphorylation of GSK-3b
Y216 [33]. Furthermore, the ability of
SB216763 to inhibit GSK-3b activity in C4-2 cells was verified by
alterations in the phosphorylation status of b-catenin, a prototyp-
ical downstream target of GSK-3b (Figure S1).
As expected, incubation with SB216763 inhibited the phos-
phorylation of GSK-3b
Y216 in both cell lines, being most
pronounced in the androgen-independent C4-2 cells (Fig. 2). Most
interestingly, an SB216763 induced decrease of GSK-3
Y216
phosphorylation in DHT-treated C4-2 cells was paralleled by an
increase in S9 phosphorylation (Fig. 2).
Figure 1. Intracellular levels of AR, GSK-3b and PSA in different
PC cell lines. (A) Intracellular AR and GSK-3b-protein levels in PC cell
lines grown in the absence of androgens. The AR-positive LNCaP,
LNCaP-SSR and C4-2 cells as well as the AR-negative PC3 cells were
grown for 48 hours under androgen-deprived conditions. Subsequent-
ly, cells were lysed and cell lysates were analyzed by Western blotting
for AR and GSK-3b. b-actin bands served as loading control. (B)
Intracellular PSA levels in CPRC cells grown under androgen-deprived
conditions. AR-positive LNCaP, LNCaP-SSR and C4-2 cells were grown
and treated as described. Relative PSA levels were determined in the
corresponding cell lysates by Western blotting as described in Material
and Methods. b-actin bands served as loading control.
doi:10.1371/journal.pone.0025341.g001
Table 1. Intracellular levels of AR, PSA and GSK-3b in different
prostate cancer cell lines.
LNCaP LNCaP-SSR LNCaP C4-2 PC3
% AR/actin 100672 2 6 611 * 377633 * 261
% PSA/actin 100610 21064 ** 437654 *** nd
% GSK-3b/actin 100625 250635
# 461618
## 192619
Western blots were performed as described under Figure 1. Protein levels of AR,
PSA, GSK-3b were quantified by densitometry and normalized to the
corresponding actin levels (loading control). Results are expressed in relation to
the corresponding LNCaP controls which were set at 100%. Each value
represents the mean of 3 independent experiments 6 standard deviation
(p-values compared to corresponding LNCaP values:
*p=0.006;
**p=0.002;
***p=0.006;
#p=0.016;
##p,0.002. nd = not determined).
doi:10.1371/journal.pone.0025341.t001
GSK-3b Inhibition in CRPC
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sublines
Nuclear localization of the AR is a prerequisite for genomic
signalling. As seen in Figure 3, the CRPC sublines LNCaP-SSR
and C4-2 exhibit high nuclear AR in the absence of androgenic
stimuli. When treated with DHT, nuclear AR was dramatically
increased in the hormone-dependent LNCaP cells, whereas the
increase in nuclear AR in LNCaP-SSR and C4-2 remained
marginal (Fig. 3, Table 2). To further analyze the ligand-
independent nuclear import of the AR in LNCaP and castra-
tion-resistant C4-2, cells were transfected with an expression
construct coding for the green fluorescent AR wild type-Eos fusion
protein (AR-EosFP) [19]. In contrast to LNCaP cells in which AR-
EosFP was only nuclear in the presence of DHT, AR-EosFP was
detectable in the nuclei of C4-2 cells in absence of androgens
(Fig. 4). This finding suggests that the predominant nuclear
localization of the AR in C4-2 cells is not due to an autonomous
function of the receptor molecule but depends on a deregulation of
cellular factors in C4-2 cells.
Figure 2. SB216763 inhibits phosphorylation of GSK-3b at
tyrosine 216. LNCaP cells and C4-2 cells were seeded into T25 flasks
and allowed to adhere overnight. After that, medium was replaced by
steroid-free medium and cells were grown for another 24 hours.
Subsequently, SB216763 (final concentration 5 mM) was added 30 min
prior to DHT (10 nM) treatment. After 4 hours, cell lysates were
analyzed for GSK-3b
Y216 and GSK-3b
S9 phosphorylation as described in
Material and Methods.
doi:10.1371/journal.pone.0025341.g002
Figure 3. Inhibition of GSK-3b by SB216763 enhances nuclear export of the AR. Cells were grown under steroid-free conditions for
24 hours. Cells were then treated with 10 nM DHT and incubated for another 30 min. Subsequently, SB216763 was added (end concentration 5 mM)
and cells were allowed to grow for another 210 min. Following this treatment, nuclear extracts were prepared and analyzed for AR and lamin A as
described in Material and Methods. AR and lamin A levels were quantified by densitometry. AR levels were expressed in fold-change AR/Lamin of cells
grown in absence of DHT and SB216763, which was set at 1.
doi:10.1371/journal.pone.0025341.g003
GSK-3b Inhibition in CRPC
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SB216763 triggers a CRM1-mediated nuclear export of
the AR in the absence of androgens
In androgen-stimulated PC cells, short term inhibition of GSK-
3b activity with various small molecule inhibitors was shown to
induce a rapid CRM1-dependent nucleocytoplasmic shuttling of
the AR. The nuclear export was independent of the mode of
action of the inhibitor used in different studies [32,19]. In order to
analyze the effects of a GSK-3b-inhibition on the androgen-
independent nuclear accumulation of the AR, CRPC cell lines
LNCaP-SSR and C4-2 were treated with the GSK-3b inhibitor
SB216763. Parental androgen-dependent LNCaP cells served as
controls (Figure 3). Treatment of C4-2 cells with SB216763
induced a rapid nuclear export of the AR in the absence/presence
of androgens as shown by densitometry of three independent
Western blots (AR-export rate in absence of DHT = 64%; in
presence of DHT = 75%) (Table 2). Androgen-independent
nuclear accumulation of the AR in the castration-resistant
LNCaP-SSR subline was also diminished following SB216763
treatment: however, the effects were less pronounced than in C4-2
cells (41% in absence of DHT; 46% in presence of DHT) (Table 2).
The nuclear export of the AR in LNCaP cells grown in the
absence of androgens remained marginal but was still detectable
(17% in absence of DHT; 7% in presence of DHT) (Table 3).
Interestingly, the nuclear export of the AR protein in C4-2 cells
grown in the absence of DHT after SB216763 treatment could be
inhibited by leptomycin B confirming a CRM1-dependent export
mechanism (Fig. 5).
Silencing and long term inhibition of GSK-3b in C4-2 cells
Using a commercial validated shRNA directed against GSK-3b
(32), we were able to dramatically reduce intracellular GSK-3b
levels in C4-2 cells (Fig. 6A). This down-regulation was paralleled
by a depletion of nuclear AR protein in C4-2 cells. Nuclear
depletion of AR protein was less pronounced when C4-2 cells were
grown in the presence of the AR-stabilizing hormone DHT
(Fig. 6A). Long term treatment of androgen-stimulated LNCaP
and 22Rv1 cells with different pharmacological GSK-3b inhibitors
has repeatedly shown that GSK-3b is involved in AR stability
[27,32]. The fact that C4-2 cells express high levels of cytoplasmic
as well as nuclear AR in the absence of androgens prompted us to
analyze the effects of SB216763 on intracellular AR levels. As seen
in Fig. 6B, long term treatment with SB216763 leads to a down-
regulation of the AR protein in C4-2 cells grown in the absence of
androgens.
AR-positive CRPC cells C4-2 and LNCaP-SSR are more
susceptible to growth inhibitory effects of the GSK-3b
inhibitor SB21676 than LNCaP cells or the AR-negative
PC3 cells
Inhibition of GSK-3b has been shown to inhibit proliferation of
AR-positive cells grown in presence of physiological levels of
androgens [27,32]. With a focus on CRPC cells, we examined the
Figure 4. Effect of SB216763 on the localization of unliganded
AR-Eos fusion protein in LNCaP and C4-2 cells. LNCaP cells and
C4-2 cells were transfected with pAR-t1EosFP and grown for 24 hours in
the absence of androgens. Thereafter, cells were treated with/without
DHT (final concentration 10 nM). After 4 hours nuclear or cytoplasmic
localisation of AR-EosFP was monitored by fluorescence microscopy.
doi:10.1371/journal.pone.0025341.g004
Table 2. Effects of SB216763 on the nuclear export of the AR.
untreated
controls SB21673 DHT
DHT +
SB216763
LNCaP 100658 3 68* 3 1 8 640 296632
#
LNCaP-SSR 100675 9 611 ** 100645 4 613
##
LNCaP C4-2 100611 3668 *** 113692 8 68
###
Western blots were performed as described under Figure 3. Nuclear AR levels
were determined by densitometry normalized to the corresponding lamin
levels (loading control). Nuclear AR levels are expressed in AR/lamin of
corresponding controls grown in absence of DHT and SB216763 (=100%). Each
value represents the mean of 3 independent experiments 6 standard deviation
(p-values compared to corresponding untreated controls:
*p=0.016;
**p=0.009;
***p=0.001; p-values compared to corresponding DHT treated controls:
#p=0.055;
##p=0.019;
###p=0.009).
doi:10.1371/journal.pone.0025341.t002
Table 3. Effect of SB216763 on the nuclear localization and
function of the AR in vivo.
LNCaP C4-2
controls SB216763 controls SB216763
% nuclear AR 74.6625.8% 76.4618% 63.4610% 27.1619.9%
% PSA 3.163,3% 0.960,9% 16.8610.6% 3.864.7%
The CAM assay was performed with C4-2 cells as described in Material and
Methods. Mean percentage 6 standard deviation of AR-positive nuclei or PSA-
positive cells were determined by 3 independent technicians counting 3–5
fields in 3–6 eggs.
doi:10.1371/journal.pone.0025341.t003
Figure 5. Treatment with leptomycin B reverses nuclear export
of the AR induced by SB216763 in C4-2 cells. C4-2 cells grown in
the absence of androgens were incubated with/without the CRM1
inhibitor leptomycin B (LMB) 30 min prior to SB216763 treatment. After
4 hours, nuclear extracts were prepared and analyzed for AR and lamin
A as described in Material and Methods.
doi:10.1371/journal.pone.0025341.g005
GSK-3b Inhibition in CRPC
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under androgen-deprived conditions. As seen in Figure 7A, AR-
positive CRPC cells grown in the absence of androgens were more
susceptible to the growth inhibitory effects of SB216763 (C4-
2.LNCaP-SSR.LNCaP). In a time course experiment (Fig. 7B),
proliferation of the AR-positive CRPC cell lines LNCaP-SSR and
C4-2 grown for 96 h in the presence of 1 mM SB216763 was
inhibited by 26% and 35% respectively. In contrast, the
proliferation rate of the parental LNCaP and the AR-negative
PC3 was only reduced by 19% and 8% when cultured under the
same conditions. In summary, the AR-positive LNCaP cells were
more susceptible to SB216763 treatment than the AR-negative
PC3 cells. The effect of SB216763 on cellular proliferation of PC
cells grown under androgen-deprived conditions was the most
pronounced in AR-positive CRPC cells (C4-2.LNCaP-
SSR.LNCaP.PC3) (Fig. 7A, B).
Inhibition of GSK-3b regulates AR-signalling by
modulating intracellular localisation of the AR in vivo
In order to simulate the effects of a GSK-3b inhibition in vivo,
we used a modified chick chorioallantoic membrane (CAM) model
[25]. SB216763 was injected into a CAM-vein allowing the
systemic spread of the compound in the chick embryo-CAM
system. The effects of SB216763 on the engrafted tumor nodules
were monitored after 48 hours by immunohistochemistry. In
contrast to the in vitro observations not only C4-2 but also LNCaP
expressed high levels of nuclear AR in vivo (nuclear AR: LNCaP:
74.6625.8%, C4-2: 63.4610%). Following SB216763 treatment
nuclear AR levels in C4-2 cells were reduced by 57% from 63.3 to
27.1% after 48 hours (Fig. 8, Table 1). Nuclear AR levels in
LNCaP remained nearly unaffected by SB216763 (LNCaP:
untreated 74.6625.8%; SB216763-treated 76.5618%) (Table 3).
The percentage of PSA-positive cells was higher in the C4-2 cell
line as compared to the parental LNCaP cell line (% of cells
staining for PSA: LNCaP 363.3% versus C4-2 16.8610.6%),
suggesting that the AR in C4-2 is active. Following SB216763
treatment the decrease of nuclear AR in C4-2 was paralleled by a
decrease in PSA-positive cells (untreated C4-2: 16.86 10.6%
versus 3.864.7% in SB216763-treated C4-2) (Fig. 8, Table 3).
Discussion
In western industrialized countries, PC presents a serious health
problem and is the second leading cause of cancer deaths in elderly
men. Although PC is very heterogeneous in its etiology, androgen
signalling is a key element in the development and progression of
PC. Initially, PC cells are largely dependent on androgens for
growth and survival. As a consequence, endocrine therapy
involving androgen depletion by surgical or medical castration,
as well as the blockade of the androgen receptor with anti-
androgens, has become a standard treatment for advanced or
metastatic disease. However, the benefit from endocrine therapies
of advanced PC is only transitory. Within a period of around 2
years, nearly all prostate cancers progress to a castration-resistant
state of the disease where they do no longer respond to standard
endocrine therapies. In the past, it has been hypothesized that the
state of CRPC was due to a clonal selection of AR-negative cells.
This assumption was mainly based on the Dunning rat tumor
model where the development of an androgen-insensitive state is
linked to the loss of the AR in tumor cells during androgen
withdrawal. However, clinical studies showed that the AR is rarely
lost but is often increased in CRPC tumor specimens and their
metastases [5,6,34,35]. The fact that in the absence of androgenic
stimuli many of the same genes that are increased by androgens in
androgen-dependent PC become elevated in CRPC supports the
notion of constitutively active AR proteins in CRPC cells [36].
This hypothesis is also supported by the observation that a
disruption of AR function inhibits proliferation of CRPC cells
grown in the absence of androgens [37].
In this report we used the AR-positive LNCaP sublines C4-2
and LNCaP-SSR which are both known to grow and survive
under androgen-deprived conditions as an in vitro tumor model for
CRPC [21,20]. We were able to show that, in contrast to the
androgen-dependent parental LNCaP cells, castration-resistant
LNCaP sublines C4-2 and LNCaR-SSR exhibited high levels of
AR and PSA when grown in the absence of androgens. Most
interestingly, the increase in intracellular AR protein levels was
paralleled by an increase in GSK-3b, a ubiquitous serine
threonine kinase shown to be an important modulator of AR
stability in vitro [32,27]. Although at the moment we are unable to
say that the dysregulation of GSK-3b levels is responsible for the
tendency of PC cells to increase intracellular AR-levels while
becoming castration resistant, our in vitro observations are in line
with a recent clinical study showing an accumulation of GSK-3b
in cells of castration-resistant tumors [38]. The detection of high
intracellular PSA levels in C4-2 and LNCaP-SSR devoid of
androgenic stimuli suggests that the AR is functionally active in
these cells even under androgen- deprived conditions.
Inordertogenerategenomicsignals,theARhastobetransported
into the nucleus. In this study, the AR was found to be
predominantly nuclear in LNCaP-SSR cells and C4-2 cells in the
absence of androgens. The reason for the androgen-independent
nuclear accumulation of full-length AR in CRPC cells remains
largelyunknown.Undernormalconditions the nucleartranslocation
Figure 6. Long term inhibition of GSK-3b in C4-2 cells. (A)
Silencing of GSK-3b in C4-2 cells. C4-2 cells were transiently transfected
with pKD-GSK-3b-v1 or pKD-NegCon-v1. 48 hours after transfection,
10 nM DHT was added where indicated. After another 24 hours, nuclear
extracts were prepared as described in Material and Methods. (B) Long
term inhibition of GSK-3b using SB216763. AR-positive C4-2 cells were
treated with increasing amounts of SB216763 for 48 hours in the
absence of androgens. Cells were lysed and cell lysates were analyzed
by Western blotting for AR. b-actin bands served as loading control.
doi:10.1371/journal.pone.0025341.g006
GSK-3b Inhibition in CRPC
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demonstrated for LNCaP. Recent findings suggest that, in order to
enter the nucleus, the AR has to undergo an intra-molecular
conformation change that brings the N- and C-termini of the
molecule into close proximity. This intra-molecular conformational
change allowing activation and nuclear translocation of an AR
monomer, prior to AR dimerization, is usually induced by ligand
binding and only occurs in living cells, not in cell lysates [39,40],
which suggests that this intra-molecular reorganization of the AR is
not protein-autonomous but depends on cellular factors. To test this
hypothesis, we subsequently transfected C4-2 and LNCaP cells with
an expression construct coding for a wild type AR fused to a green
Eos fluorescent protein (EosFP) [41]. In the presence of DHT AR-
EosFP was detectable in the nuclei of both LNCaP and C4-2. When
grown in the absence of DHT, AR-EosFP was only detectable in the
nuclei of castration-resistant C4-2 cells but not in the nuclei of
androgen-dependent LNCaP cells. This observation is consistent
with a similar experiment demonstrating a robust nuclear localiza-
tion of a GFP-tagged AR transfected into C4-2 cells [42]. Taken
together, these findings suggest that the nuclear localization of full-
length AR in CRPC does not necessarily require hormone binding
and may instead be regulated by other factors.
As recently shown by our group, short term inhibition of the
serine/threonine kinase GSK-3b by small molecule inhibitors
induced a rapid, CRM1-dependent nucleocytoplasmic shuttling of
the AR in androgen-treated cells [19]. As GSK-3b is overex-
pressed in CRPC cells in vivo and in vitro, we hypothesized that the
enzyme might also be part of a putative protein complex involved
Figure 7. Inhibition of GSK-3b by SB216763 inhibits the proliferation in CRPC cells. AR-positive LNCaP, LNCaP-SSR and C4-2 cells as well as
the AR-negative PC3 cells, were treated with increasing amounts of SB216763 for 48 hours (A) or with/without 1 mM SB216763 for 0, 24 and 96 hours
(B). Proliferation was measured using an MTT assay as described in Material and Methods. Results shown under (A) are expressed as % of untreated
controls 6 standard deviation. Results shown under (B) are expressed in percent of SB216763-treated/untreated control which was set at 100% for
the time point zero 6 standard deviation.
doi:10.1371/journal.pone.0025341.g007
GSK-3b Inhibition in CRPC
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supported by a previous finding showing that GSK-3b is highly
phosphorylated at tyrosine 216 (Y216), the activation function of
the enzyme, in C4-2 cells [30]. The increase of GSK-3b
Y216
phosphorylation in LNCaP cells following DHT treatment (Fig. 2)
furthermore suggests an important role for GSK-3b in AR
signalling under normal conditions. In an attempt to disrupt the
predominant nuclear localization of the AR in CRPC cells, we
treated castration-resistant C4-2 and LNCaP-SSR as well as the
parental LNCaP with the maleimide SB216763. This highly
potent compound is known to inhibit intramolecular tyrosine
kinase activity of the GSK-3b molecule, the latter being
responsible for its autophosphorylation at Y216 [33]. As seen in
Figure 2, the GSK-3b inhibitor SB216763 is able to decrease
Y216-phosphorylation of GSK-3b in LNCaP as well as in C4-2
cells. Following treatment with SB216763, the nuclear accumu-
lation of the AR in the castration- resistant LNCaP sublines C4-2
and LNCaP-SSR was dramatically reduced in the presence, and
most importantly in the absence, of DHT, being most pronounced
in C4-2 cells (Table 2). Nucleocytoplasmic shuttling of the AR
after GSK-3b-inhibition in C4-2 cells grown in the absence of
DHT could be reversed by leptomycin B (LMB), suggesting a
CRM1-dependent export mechanism (Fig. 5). In a previous study,
we identified a CRM1 binding site in the C-terminus of the AR
[19]. Due to its vicinity to the ligand binding domain, we
hypothesized that hormone binding could regulate the accessibility
of the CRM1 binding site, thereby modulating the nuclear export
of the AR. The observation that the AR can be exported from the
nuclei of CRPC cells growing in the absence of androgens is an
important novel finding, clearly demonstrating that the nuclear
export of the AR following GSK-3b inhibition is not due to a
modulation of hormone binding properties of the receptor.
The fact that short term inhibition of GSK-3b (max. 4 hours)
leads to a rapid export of the AR prompted us to analyze the
effects of a long term inhibition of the enzyme in AR-positive
CRPC-cells. Silencing of GSK-3b using specific shRNA led to a
depletion of nuclear AR in C4-2 cells. Nuclear depletion of AR
protein was less pronounced in C4-2 cells grown in the presence of
the AR-stabilizing hormone DHT. Although these findings
support the assumption that inhibition of GSK-3b triggers the
nucleocytoplasmic shuttling of the AR, the data derived from the
long term shRNA-experiments must be interpreted carefully.
Short term inhibition of GSK-3b activity by small molecules like
SB216763 was repeatedly shown to induce a rapid, CRM1-
dependent nuclear export of the AR in PC cells [19,32]. In
contrast to these findings, the long-term inhibition of GSK-3b
caused a proteasomal degradation of the AR protein [32]. Because
GSK-3b triggers AR localization as well as AR stability, we
hypothesize that the dramatic depletion of nuclear AR in C4-2
cells following GSK-3b silencing is due to a combination of
nuclear export and proteasomal degradation of the receptor
molecule.
The fact that inhibition of GSK-3b affects AR function as well
as AR stability prompted us to analyze the effects of a GSK-3b
inhibition on the proliferation of PC cells in vitro. Response to
treatment of PC cells with SB216763 was most pronounced in AR-
positive CRPC cells (inhibition of cell growth: C4-2.LNCaP-
SSR.LNCaP.PC3). The ability of SB216763 to inhibit cellular
proliferation was paralleled by its ability to induce a CRM1-
dependent export of the AR in PC cells.
In order to test the efficacy of GSK-3b inhibitors as potential
therapeutic agents, we extended our studies to a CAM-xenograft
model. To our surprise the AR was predominantly nuclear in
LNCaP xenografts as well as in C4-2 xenografts. A possible
explanation for this could be the production of androgens by the
host organism. Moreover, the AR of LNCaP and its derivatives is
carrying a point mutation (T877A) leading to a promiscuous AR
that can, at least in part, be activated by various non-androgenic
steroids [43,44]. Nevertheless, the AR of C4-2 as compared to the
AR of the parental LNCaP is more active in the CAM-Xenograft
model, as documented by intracellular PSA levels (cells positive for
PSA: LNCaP 3,1% and C4-2 16.8%). Following a 48-hour
treatment with SB216763, nuclear AR levels of C4-2 cells were
significantly reduced, which was paralleled by a considerable
reduction in intracellular PSA levels. In contrast to results in C4-2
cells the effects on AR and PSA in LNCaP cells remained
insignificant.
Taken together our study demonstrates that (1) overexpression
of the AR in CPRC cells is paralleled by an increase in
intracellular GSK-3b, (2) the effects of GSK-3b on AR signalling
are not due to a modulation of DHT binding to the AR, (3)
nuclear accumulation of the AR in CRPC cells is not an
autonomous function of a mutated AR receptor but is mediated
by deregulated cellular factors, such as GSK-3b, (4) GSK-3b and
CRM1 are part of a putative complex controlling the nuclear
localization of the AR in CRPC cells, and (5) inhibition of GSK-3b
activity by small molecule inhibitors induces a rapid nuclear
export of the AR in CRPC cells in vitro and in vivo thereby
modulating AR signalling.
The dependence of CRPC on transcriptionally active AR has
resurged the interest in developing inhibitors targeting the AR or
androgen axis. Next generation hormone therapies recognize the
fact that in CRPC the AR can be activated by intrinsic production
of tissue androgens as well as by peptide growth factors. Among
hormonal agents currently being tested are CYP17 inhibitors like
abiraterone, TAK-700 and TOK-001 or the second generation
anti-androgen MDV-3100 [45]. Small molecule inhibitors like
EPI-001 and sintokamide targeting the transactivation domain at
the N-terminus of the AR have shown encouraging results in vitro
as well as in experimental animal models [46,47]. Our results
suggest that simultaneous targeting of AR nuclear export as well as
AR-stability by GSK-3b inhibitors is a further valuable strategy to
diminish AR signalling in CRPC. Moreover, the combination of
GSK-3b inhibitors with novel AR inhibitors might be a useful
approach for the treatment of advanced CRPC.
Figure 8. Inhibition of GSK-3b diminishes nuclear localization
and function of the AR in vivo. The CAM assay was performed with
C4-2 cells. Subsequently, nuclear localization of the AR and intracellular
PSA distribution in untreated and SB216763-treated tumor-nodules
(magnification 400x) was performed as described in Material and
Methods. AR-positive cells are marked with stars.
doi:10.1371/journal.pone.0025341.g008
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Chemicals
GSK-3b inhibitor SB216763 (3-(2, 4-dichlorophenyl)-4-(1-
methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione) was provided by
Biomol GmbH, Hamburg, Germany. Phosphatase inhibitor
cocktail tablets (Phos-Stop), protease inhibitor cocktail tablets
(Complete Mini) and dithiothreitol (DTT) were obtained from
Roche Diagnostics GmbH, Mannheim, Germany. Leptomycin B
was a product of Alexis Biochemicals, Lo ¨rrach, Germany.
Dihydrotestosterone (DHT), HEPES, ethylene-diamine-tetra-ace-
tic acid (EDTA) and Tween 20 were provided by Sigma-Aldrich
GmbH, Taufkirchen, Germany. Bovine serum albumin (BSA) was
provided by PAA Laboratories GmbH, Pasching, Austria. Sodium
dodecyl sulphate (SDS), Nonidet NP40 (NP40) and Glycine were
products of AppliChem GmbH, Mannheim, Germany. All other
chemicals, if not specified, were purchased from Sigma-Aldrich
GmbH, Taufkirchen, Germany. GSK-3b-directed shRNA (pkD-
GSK-3b-v1) or control shRNA (pkD-NegCon-v1) were products
of Upstate Biotechnology, Lake Placid, NY.
Antibodies
Antibodies for Western blotting: AR rabbit monoclonal
antibody (Epitomics, Clone EP670Y) directed against the C-
terminal end of the AR was purchased from Biomol, Hamburg,
Germany. Polyclonal rabbit antibodies to pGSK-3b (Y216) and
Lamin A (H102) as well as mouse monoclonal antibodies to PSA
(CHYH2) and GSK-3b (1F7) were provided by Santa Cruz
Biotechnology, Heidelberg, Germany. Mouse monoclonal anti-
body AC-15 to b-actin was purchased from Sigma Aldrich GmbH,
Taufkirchen, Germany. Anti pGSK-3b (Ser 9) (D3A4) and anti-
mouse and anti-rabbit IgG-horseradish peroxidase linked anti-
bodies were products of Cell Signalling Technology, Frankfurt
a.M., Germany.
Antibodies for histochemistry: Mouse monoclonal antibodies
directed against PSA (ER-PR8) and AR (AR-441) were products
of DAKO Diagnostica, Hamburg, Germany. Immunohistochem-
ical detection/staining of primary antibodies was performed using
Histostain Plus, Invitrogen, Darmstadt, Germany, according to
the manufactures instructions.
Cell culture
AR-negative PC3 cells and AR-positive LNCaP cells were
provided by the American Type Culture Collection, Manassas,
VA, USA. CRPC cell lines C4-2 and LNCaP-SSR were provided
by Prof. Sven Reske, Ulm, Germany and Prof. Martin Burchardt,
Greifswald, Germany. RPMI-1640, phosphate buffered saline
(PBS) and penicillin/streptomycin solution were products of PAA
Laboratories, Linz, Austria. Fetal bovine serum (FBS) and steroid-
free dextran-charcoal-treated FBS (FBSdcc) were obtained from
BioWest, Nuaille, France. Cell culture plastic ware was purchased
from Sarstedt, Nu ¨rmbrecht, Germany. LNCaP cells and PC3 cells
were routinely cultured in RPMI-1640, 1% penicillin/streptomy-
cin (v/v), 10% FBS (v/v) whereas LNCaP-SSR and C4-2 were
routinely grown in RPMI-1640 supplemented with 1% penicillin/
streptomycin (v/v) and 10% steroid-free dextran charcoal-treated
FBS (FBSdcc) (v/v). During experiments, cells were maintained in
RPMI-1640 with 2.5% FBSdcc (v/v) and antibiotics in the
presence/absence of DHT and the GSK-3b-inhibitor SB216763.
Preparation of whole or nuclear cell extracts
For the preparation of whole cell extracts, cells grown in T25
flasks were incubated with 500 ml lysis buffer (50 mM Tris, 5 mM
EDTA, 150 mM NaCl, 1% triton X 100 (v/v), pH 7.3)
supplemented with phosphatase and protease inhibitors according
to the manufactures instructions. Subsequently, cells were scraped
thoroughly out of the flask. Cell lysates were centrifuged at
15000 xg for 15 minutes at 4uC in a tabletop centrifuge.
Supernatants were collected and protein concentrations were
determined using the BCA-Protein Assay (Pierce, Rockford, IL,
USA). Whole cell extracts were subjected to Western blot analysis.
Nuclear extracts were prepared as recently described [19].
Briefly, cells grown in T25 flasks were lysed in 500 ml buffer A
(10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT,
0.05% NP40, pH 7.9) and centrifuged 10 minutes at 3000xg to
collect cytoplasmic fractions. Residual pellets containing the nuclei
were resuspended in 93.5 ml buffer B (5 mM HEPES, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 26% glycerol (v/v),
pH 7.9) and 6.5 ml of 4.6 M NaCl and centrifuged at 15000xg to
remove nuclear debris. Extracts were analysed by Western
blotting.
Western blot analysis and immunodetection
Whole cell extracts or nuclear fractions (30 mg) were subjected
to electrophoresis in a 10% SDS-PAGE and electroblotted onto
nitrocellulose membranes (Pall, Bad Kreuznach, Germany).
AR, PSA and GSK-3b were detected as follows: Non-specific
binding sites on the nitrocellulose were blocked by incubation with
5% (w/v) non-fat dry milk (Sucofin, TSI GmbH, Zeven,
Germany) in PBST (PBS + 0,1% Tween20). Antibodies were
applied in PBST supplemented with 1% not-fat dry milk as
follows: AR antibody (EP670Y) 1:2000; PSA antibody (CHYH2)
1:500; GSK-3b antibody (1F70) 1:500 and antibodies serving as
loading controls for cytoplasm/nucleus, i.e., b-Actin antibody
(AC15) 1:20000 and Lamin A antibody (H102) 1:1000. Resulting
immunocomplexes were detected using horseradish peroxidase-
labelled goat anti-rabbit antibody 1:2000 and goat anti-mouse
antibody 1:2000 (1:5000 for the detection of AC-15 to b-Actin).
Immunoreactive bands were visualized by direct detection with
Super Signal West Pico and Dura Chemiluminescence Substrates
(Pierce, Rockford, IL, USA) using ChemiSmart 500 Vilber
Lormat (Marne-la-Valle, France). Immunoreactive bands were
quantified by densitometry using ChemiCapt/Bio1D software
from Vilber Lormat.
Immunodetection of site specific phosphorylation in GSK-3b
(pGSK-3b
Y216 or pGSK-3b
S9) was performed using the following
modifications: Nitrocellulose membranes were blocked in PBST
supplemented with 5% BSA. Subsequently membranes were
incubated with a phosphospecific antibody to pGSK-3b (Y216)
diluted in PBST with 1%BSA (w/v) at 1:500. Immunoreactive
bands were detected and visualized as described above. After
detection of pGSK-3b
Y216 the phosphospecific antibody was
removed by incubating the membrane 2610 minutes in stripping
buffer (1.5% Glycin (w/v), 0,1% SDS (w/v), 1%Tween-20 (v/v),
pH 2,2). Following three washing steps (3610 min) in PBST, the
nitrocellulose membrane was blocked in PBST supplemented with
5% BSA and reprobed with the pGSK-3b (S9) antibody (1:1000).
Subsequently, the membrane was stripped once again and
reprobed with the GSK-3b antibody (1F7) (1:500), serving as a
loading control. Immunoreactive GSK-3b bands were detected
and quantified as described above.
Nuclear translocation assay
Nuclear translocation of the AR was analyzed in LNCaP and
C4-2 cells transfected with pAR-t1EosFP, an expression plasmid
coding for a green fluorescent AR-Eos fusion protein (AR-EosFP)
[22]. Twenty four hours after transfection cells were treated with/
without SB216763 in the presence/absence of DHT [19].
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Silencing of GSK-3b in prostate cancer cells C4-2 cells
C4-2 cells were transiently transfected with shRNA-expression
plasmids directed against GSK-3b (pkD-GSK-3b-v1) or with
control shRNA (pkD-NegCon-v1) as recently described [32]. High
transfection efficiency was achieved in the LNCaP C4-2 subline
using Attractene Transfection Reagent, Qiagen, Hilden, Ger-
many.
Cell viability assay
Cell viability was determined by means of a colorimetric MTT-
assay measuring the reduction of tetrazolium salts to formazan
derivatives by functional mitochondria. The assay was performed
as originally described [23].
Chorioallantoic membrane assay (CAM Assay)
In order to analyze the effects of a GSK-3b inhibition in vivo,w e
used a chick chorioallantoic membrane (CAM) assay as an animal
substitute model [24]. In this assay, shells of fertilized chicken eggs
were opened on day 8 and silicon rings (5 mm in diameter) were
applied onto the CAM. 10
6 cells were seeded into the ring in 20 ml
50% Matrigel (v/v) (BD Biosciences, Heidelberg, Germany)
dissolved in serum and antibiotic-free RPMI-1640. Tumor grafts
were allowed to grow for 48 hours. In contrast to the classical
CAM assay, the GSK-3b inhibitor SB216763 was not applied
topically. Instead 50 ml of the GSK-3b inhibitor [normal saline,
2% Dimethylsulfoxide (v/v), 100 mM SB216763] were injected
into a CAM vein [25], allowing the systemic spread of the
compound in the chick embryo CAM system for 48 hours.
Subsequently, tumor tissues were fixed, paraffin embedded, and
serially sectioned. The effects of SB216763 on AR and PSA in the
engrafted tumor nodules were monitored by immunohistochem-
istry (antibodies to AR, (AR-441) 1:500; and to PSA (ER-PR8)
1:25) as previously described [24,25].
Statistical Analysis
The Mann-Whitney U test was used to evaluate distribution
difference across two groups. Statistical significance in this study
was set as p#0.05.
Supporting Information
Figure S1 Phosphorylation of the GSK-3b downstream
target b-catenin. AR-positive C4-2 cells were treated with
increasing amounts of SB216763 for 24 hours in the presence/
absence of DHT. Cell extracts were analyzed by Western blotting
as described in Material and Methods. Phosphorylated forms of b-
catenin were determined using a rabbit polyclonal Phospho-b-
Catenin(Ser33/37/Thr41) antibody (Cell Signaling Technology,
New England Biolabs, Frankfurt a.M., Germany). Subsequently,
membranes were stripped and reprobed with an antibody directed
against native b-catenin (rabbit monoclonal antibody, Epitomics)
which served as a control.
(TIF)
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